Literature DB >> 20524825

Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.

Kaisorn L Chaichana1, Aditya N Halthore, Scott L Parker, Alessandro Olivi, Jon D Weingart, Henry Brem, Alfredo Quinones-Hinojosa.   

Abstract

OBJECT: The median survival duration for patients with glioblastoma is approximately 12 months. Maximizing quality of life (QOL) for patients with glioblastoma is a priority. An important, yet understudied, QOL component is functional independence. The aims of this study were to evaluate functional outcomes over time for patients with glioblastoma, as well as identify factors associated with prolonged functional independence.
METHODS: All patients who underwent first-time resection of either a primary (de novo) or secondary (prior lower grade glioma) glioblastoma at a single institution from 1996 to 2006 were retrospectively reviewed. Patients with a Karnofsky Performance Scale (KPS) score ≥ 80 were included. Kaplan-Meier, log-rank, and multivariate proportional hazards regression analyses were used to identify associations (p < 0.05) with functional independence (KPS score ≥ 60) following glioblastoma resection.
RESULTS: The median follow-up duration time was 10 months (interquartile range [IQR] 5.6-17.0 months). A patient's preoperative (p = 0.02) and immediate postoperative (within 2 months) functional status was associated with prolonged survival (p < 0.0001). Of the 544 patients in this series, 302 (56%) lost their functional independence at a median of 10 months (IQR 6-16 months). Factors independently associated with prolonged functional independence were: preoperative KPS score ≥ 90 (p = 0.004), preoperative seizures (p = 0.002), primary glioblastoma (p < 0.0001), gross-total resection (p < 0.0001), and temozolomide chemotherapy (p < 0.0001). Factors independently associated with decreased functional independence were: older age (p < 0.0001), coexistent coronary artery disease (p = 0.009), and incurring a new postoperative motor deficit (p = 0.009). Furthermore, a decline in functional status was independently associated with tumor recurrence (p = 0.01).
CONCLUSIONS: The identification and consideration of these factors associated with prolonged functional outcome (preoperative KPS score ≥ 90, seizures, primary glioblastoma, gross-total resection, temozolomide) and decreased functional outcome (older age, coronary artery disease, new postoperative motor deficit) may help guide treatment strategies aimed at improving QOL for patients with glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524825      PMCID: PMC3725949          DOI: 10.3171/2010.4.JNS091340

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  45 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  Levetiracetam: preliminary experience in patients with primary brain tumours.

Authors:  G L Wagner; E B Wilms; C A Van Donselaar; Ch J Vecht
Journal:  Seizure       Date:  2003-12       Impact factor: 3.184

3.  The UK FIM+FAM Extended Activities of Daily Living module: evaluation of scoring accuracy and reliability.

Authors:  Janet Law; Beverley Fielding; Diana Jackson; Lynne Turner-Stokes
Journal:  Disabil Rehabil       Date:  2009       Impact factor: 3.033

4.  Quantitative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective cohort.

Authors:  L Recht; M Glantz; M Chamberlain; C C Hsieh
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 5.  Primary and secondary glioblastomas: from concept to clinical diagnosis.

Authors:  P Kleihues; H Ohgaki
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

Review 6.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

Review 7.  Factors influencing survival in high-grade gliomas.

Authors:  Jan C Buckner
Journal:  Semin Oncol       Date:  2003-12       Impact factor: 4.929

8.  Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project.

Authors:  Susan M Chang; Ian F Parney; Michael McDermott; Fred G Barker; Meic H Schmidt; Wei Huang; Edward R Laws; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew E Sloan; Mitchel Berger
Journal:  J Neurosurg       Date:  2003-06       Impact factor: 5.115

9.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.

Authors:  Edward R Laws; Ian F Parney; Wei Huang; Fred Anderson; Angel M Morris; Anthony Asher; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew Sloan; Mitchel S Berger; Susan Chang
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

10.  Are there meaningful longitudinal changes in health related quality of life--SF36, in cardiac rehabilitation patients?

Authors:  Gabrielle McKee
Journal:  Eur J Cardiovasc Nurs       Date:  2008-05-27       Impact factor: 3.908

View more
  33 in total

1.  Comparing high-resolution microscopy techniques for potential intraoperative use in guiding low-grade glioma resections.

Authors:  Daphne Meza; Danni Wang; Yu Wang; Sabine Borwege; Nader Sanai; Jonathan T C Liu
Journal:  Lasers Surg Med       Date:  2015-04-14       Impact factor: 4.025

2.  Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastoma.

Authors:  Thomas W Link; Graeme F Woodworth; Kaisorn L Chaichana; Stuart A Grossman; Robert S Mayer; Henry Brem; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  J Clin Neurosci       Date:  2012-05-15       Impact factor: 1.961

3.  An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.

Authors:  Peiman Haddad; Sohrab Shazadi; Farhad Samiei; Homayoun Hadizadeh Kharrazi; Morteza Tabatabaeefar; Afshin Rakhsha; Mohammad Faranoosh; Mohammad Torabi-Nami; Ali Dadras; Atieh Liaghi; Leila Nafarieh
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines.

Authors:  J Capellades; P Teixidor; G Villalba; C Hostalot; G Plans; R Armengol; S Medrano; A Estival; R Luque; S Gonzalez; M Gil-Gil; S Villa; J Sepulveda; J J García-Mosquera; C Balana
Journal:  Clin Transl Oncol       Date:  2016-12-22       Impact factor: 3.405

Review 5.  Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.

Authors:  Kaisorn L Chaichana; Leon Pinheiro; Henry Brem
Journal:  Ther Deliv       Date:  2015-03

6.  Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.

Authors:  Jaume Capellades; Josep Puig; Sira Domenech; Teresa Pujol; Laura Oleaga; Angels Camins; Carles Majós; Rocio Diaz; Christian de Quintana; Pilar Teixidor; Gerard Conesa; Gerard Plans; Josep Gonzalez; Natalia García-Balañà; Jose Maria Velarde; Carmen Balaña
Journal:  J Neurooncol       Date:  2017-12-28       Impact factor: 4.130

7.  Glioblastoma survival in the United States before and during the temozolomide era.

Authors:  Derek R Johnson; Brian Patrick O'Neill
Journal:  J Neurooncol       Date:  2011-11-02       Impact factor: 4.130

Review 8.  Factors influencing quality of life in adult patients with primary brain tumors.

Authors:  Rakesh Jalali; Debnarayan Dutta
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.

Authors:  Melissa Kerkhof; Janneke C M Dielemans; Melanie S van Breemen; Hanneke Zwinkels; Robert Walchenbach; Martin J Taphoorn; Charles J Vecht
Journal:  Neuro Oncol       Date:  2013-05-16       Impact factor: 12.300

10.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.